Novavax - NVAX Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last twelve months. There are currently 2 sell ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVAX, but not buy additional shares or sell existing shares.
View NVAX analyst ratings or view top-rated stocks.

7 equities research analysts have issued 12 month price targets for Novavax's shares. Their NVAX share price forecasts range from $27.00 to $207.00. On average, they anticipate the company's stock price to reach $109.25 in the next year. This suggests a possible upside of 556.6% from the stock's current price.
View analysts price targets for NVAX or view top-rated stocks among Wall Street analysts.

Novavax's stock was trading at $143.07 at the beginning of the year. Since then, NVAX shares have decreased by 88.4% and is now trading at $16.64.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our NVAX earnings forecast.

Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings data on Tuesday, November, 8th. The biopharmaceutical company reported ($2.15) EPS for the quarter, missing the consensus estimate of $2.21 by $4.36. The biopharmaceutical company had revenue of $734.58 million for the quarter, compared to analysts' expectations of $555.50 million. Novavax had a negative trailing twelve-month return on equity of 572.54% and a negative net margin of 71.59%. Novavax's revenue for the quarter was up 310.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($4.31) earnings per share.

Novavax shares reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Novavax issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.00 billion-$2.00 billion, compared to the consensus revenue estimate of $2.04 billion.

46 employees have rated Novavax Chief Executive Officer Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Novavax's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.55%), State Street Corp (4.66%), Credit Suisse AG (1.20%), Renaissance Technologies LLC (1.12%), Coatue Management LLC (0.70%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends.

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVAX stock can currently be purchased for approximately $16.64.

Novavax (NASDAQ:NVAX) has a market capitalization of $1.31 billion and generates $1.15 billion in revenue each year. The biopharmaceutical company earns $-1,743,750,000.00 in net income (profit) each year or ($17.30) on an earnings per share basis.

The company employs 1,541 workers across the globe.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for the company is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100.